Trials / Not Yet Recruiting
Not Yet RecruitingNCT06935149
Detecting Colorectal Cancer With Liver Metastatic Lesions Using Novel Precise Imaging Tools
Detecting Liver Metastatic Lesions in Patients of Colorectal Cancer With Novel Precise Imaging Tools
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 5 (estimated)
- Sponsor
- Primo Biotechnology Co., Ltd · Industry
- Sex
- All
- Age
- 20 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
This study will demonstrate the diagnostic utility of PSMA PET among patients with CRC with liver metastasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 18-PSMA | Intravenous push 4 MBq/kg per patient (for a 70 kg patient, 280 MBq of \[18F\]FPSMA needs to be intravenously injected), and the maximum dose cannot exceed 400 MBq. After the injection of \[18F\]FPSMA, intravenous flushing was performed with 20 ml of normal saline. |
Timeline
- Start date
- 2025-05-01
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
- First posted
- 2025-04-20
- Last updated
- 2025-04-24
Source: ClinicalTrials.gov record NCT06935149. Inclusion in this directory is not an endorsement.